Network topologies and convergent aetiologies arising from deletions and duplications observed in individuals with autism by Noh, Hyun Ji et al.
Network Topologies and Convergent Aetiologies Arising
from Deletions and Duplications Observed in Individuals
with Autism
Hyun Ji Noh1, Chris P. Ponting1, Hannah C. Boulding1, Stephen Meader1, Catalina Betancur2,3,4,
Joseph D. Buxbaum5, Dalila Pinto6, Christian R. Marshall7, Anath C. Lionel7, Stephen W. Scherer7,
Caleb Webber1*
1MRC Functional Genomics Unit, University of Oxford, Department of Physiology, Anatomy, and Genetics, Oxford, United Kingdom, 2 INSERM U952, Paris, France, 3CNRS
UMR 7224, Paris, France, 4UPMC Universite´ Paris 06, Paris, France, 5 The Seaver Autism Center for Research and Treatment, Department of Psychiatry, Mount Sinai School
of Medicine, New York, New York, United States of America, 6Departments of Psychiatry, and Genetics and Genomic Sciences, Seaver Autism Center, The Mindich Child
Health & Development Institute, Mount Sinai School of Medicine, New York, New York, United States of America, 7 The Centre for Applied Genomics and Program in
Genetics and Genome Biology, The Hospital for Sick Children and the McLaughlin Centre and Department of Molecular Genetics, University of Toronto, Toronto, Ontario,
Canada
Abstract
Autism Spectrum Disorders (ASD) are highly heritable and characterised by impairments in social interaction and
communication, and restricted and repetitive behaviours. Considering four sets of de novo copy number variants (CNVs)
identified in 181 individuals with autism and exploiting mouse functional genomics and known protein-protein interactions,
we identified a large and significantly interconnected interaction network. This network contains 187 genes affected by
CNVs drawn from 45% of the patients we considered and 22 genes previously implicated in ASD, of which 192 form a single
interconnected cluster. On average, those patients with copy number changed genes from this network possess changes in
3 network genes, suggesting that epistasis mediated through the network is extensive. Correspondingly, genes that are
highly connected within the network, and thus whose copy number change is predicted by the network to be more
phenotypically consequential, are significantly enriched among patients that possess only a single ASD-associated network
copy number changed gene (p= 0.002). Strikingly, deleted or disrupted genes from the network are significantly enriched in
GO-annotated positive regulators (2.3-fold enrichment, corrected p= 261025), whereas duplicated genes are significantly
enriched in GO-annotated negative regulators (2.2-fold enrichment, corrected p= 0.005). The direction of copy change is
highly informative in the context of the network, providing the means through which perturbations arising from distinct
deletions or duplications can yield a common outcome. These findings reveal an extensive ASD-associated molecular
network, whose topology indicates ASD-relevant mutational deleteriousness and that mechanistically details how
convergent aetiologies can result extensively from CNVs affecting pathways causally implicated in ASD.
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Introduction
Autism Spectrum Disorders (ASD) form a group of complex
disorders affecting ,1% of individuals [1]. ASD are characterised
by impairments in social interaction, communication, and
restricted and repetitive interests and behaviours [2], although
other symptoms such as intellectual disability, seizures or auditory
abnormalities frequently co-occur [3]. Despite the high estimates
of heritability for ASD found from monozygotic twin studies
(,90%) [4], the genetic cause is recognized in only ,20% of cases
suggesting that there are many causal variants yet to be identified
[5,6]. ASD-causative alleles are likely to be rare as (i) they are
under strong purifying selection from the population due to the
low fertility (,5%) of individuals with ASD [7], and (ii) there is a
strong positive correlation between paternal age and ASD risk
which suggests that ASD-contributing mutations frequently may
be arising de novo in the continuously-replicating paternal germ line
[8]. Thus, in this study we examine de novo variants, specifically de
novo copy number variants (CNVs), found in individuals with ASD
as a set of variants likely enriched in causal mutations [6].
By contrast to methods that require either recurrent or common
genetic variation to identify disease-associated loci, functional
enrichment analysis (FEA) approaches gain considerable power by
simultaneously examining the contributions of many disparate
variants across many individuals’ genomes and thus may be
particularly appropriate for investigating the many rare and
distributed variants underlying autism [9,10]. FEA approaches
hypothesise that dispersed variants observed in patients with
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shared symptoms may be affecting genes that participate in a
common biological process and it is the disruption of the same
process within each of these patients that underlies their common
symptoms [11,12]. Thus, FEA considers whether there is a
functional category that is exceptionally common for genes
overlapped by dispersed CNVs identified in the genomes of
patients that present the same disorder. It thus associates function
with the disorder and nominates those copy number variable genes
that participate in that function as candidate disease genes [9].
The functional category types used in FEA approaches are key
to the biological insights that they can provide. Different
approaches have been applied to investigate the genetics
underlying autism, including literature annotations [6,13],
protein-protein interactions [14,15], mouse model phenotypes
[13], gene co-expression [16] and functional linkage networks
[6,17]. As the application of these different approaches in autism
studies often accompanies the publication of a novel genetic
dataset, each method has highlighted many, usually novel,
candidate genes that add to a rapidly growing list [18] and
replication of significant functional enrichments has only rarely
been attempted, let alone achieved [13,19]. Synaptic functioning
has been recurrently associated with ASD by many of the recent
studies [13,17] but the small proportions of genes that form these
associations along with the functional diversity broadly exhibited
by genes implicated in ASD has led authors to question specific
associations [20]. However, given that it appears likely that the
variants of several hundred genes contribute to autism [6],
identifying those biological process(es) that are commonly
disrupted may provide a more explanatory approach than to
collate individual causative genes. In particular, FEA, when
applied to ASD CNVs, should not just aim to identify unifying
functional themes but should also provide a framework for
interpreting how these variants exert their proposed phenotypic
effects.
In this study, we examined the genes affected by four
previously-published sets of rare, de novo CNVs identified in
autistic patients. Given that ASD is a behavioural disorder, we
initially considered the phenotype-level gene associations provid-
ed by mouse gene models before moving on to consider more
molecular gene descriptions. We identified a significant enrich-
ment of genes whose orthologues’ disruption in mouse yields an
abnormal synaptic transmission phenotype in 3 of 4 sets. We show that
the protein products of the genes contributing to these
enrichments form an extensive physical interaction network with
genes previously implicated in autism and that extends to many
other genes located in CNVs (herein termed CNV genes). We
show that many of the autistic individuals considered here possess
multiple CNV genes that reside within the network, suggesting
extensive epistasis, and provide evidence that the number of
interactions a gene has within the network is related to the
propensity of its copy change to cause autism. Finally, within this
network we find that whereas genes deleted in ASD are
significantly enriched in those that positively regulate biological
processes, the converse is also true: genes that are duplicated are
enriched in negative regulators of biological processes. We
provide several examples of how the direction of copy number
change reinforces the biological interpretation of the ASD-
associated physical interaction network.
Results
Initially, we sought to objectively identify autism-related mouse
behaviours among phenotypes that are over-represented among de
novo CNV genes for individuals with ASD (herein termed ASD dn
CNVs). For this, we obtained 4 sets of ASD dn CNVs (Table S1
and Materials and Methods). The set collated by the AGP is likely
to be most powerful due both to its higher number of CNVs and
their generally smaller sizes, although all methodologies employed
in this study account for variations in the numbers of genes
affected by each CNV set (Table S2). We considered Gain or Loss
CNVs separately, in addition to the set formed from their union
(All).
Many mouse model phenotypes are associated with ASD
dn CNVs
The Mammalian Phenotype Ontology, the set of terms by
which the MGI annotates the phenotypes of mouse models, is
organised at its highest level into 30 over-arching phenotypes [21].
Of these, three categories (Behavior/Neurological, Hearing/Vestibular/
Ear and Lethality-Postnatal) were significantly over-represented by
AGP ASD dn CNV genes compared to expectation by random
chance, thus associated with AGP ASD dn CNV genes (BH-
adjusted one-sided Fisher’s test p,5%; Table S3). Importantly,
these significant associations are all specific to Gain CNVs (2.0–2.7-
fold increases) whilst observed counts for Loss CNVs differ little
from expected values (data not shown).
The significant enrichments of these three overarching catego-
ries with the AGP ASD dn CNVs then provided the rationale
necessary for testing of all their finer-scale phenotypic terms for
association (162, 218 and 2 terms, for Behaviour/Neurological,
Hearing/Vestibular/Ear and Lethality-Postnatal categories, respective-
ly; see Materials and Methods). Although the Nervous System
phenotypic category was not significantly over-represented among
ASD dn CNV genes (All AGP ASD dn CNVs: 1.3-fold increase,
p=0.03, BH-adjusted p.5%), the behavioural presentations of
ASD are likely to be manifestations of nervous system abnormal-
ities. Consequently, we also tested for significant enrichments of
finer-scale phenotypes within this category (282 terms). Subse-
quently, 23 behavioural, 21 nervous system, 27 hearing and 1
postnatal-lethality phenotypes were identified as being significantly
enriched among the AGP ASD dn CNV genes (BH-adjusted
Author Summary
Autism Spectrum Disorders (ASD) are characterised by
impairments in social interaction and communication, and
restricted and repetitive behaviours. ASD are highly
heritable and many different stretches of DNA have been
found to be duplicated or deleted in individuals with ASD.
We found that an unusually high number of genes
affected by these DNA deletions/duplications are associ-
ated with the functioning of synaptic transmission
between nerve cells. The proteins made by many of
these genes are known to interact with each other and,
together with proteins from other deleted/duplicated
genes, form a large interlinked biological network. This
network was affected by almost 50% of the deletions/
duplications in the ASD patients considered. Many
individual ASD patients had deletions or duplications of
multiple genes within this network, but for those patients
with just a single gene from the network changed, that
single gene appeared to play an important role. Further-
more, the network predicts that the effects arising from
the genes in the deletions are similar to the effects arising
from the genes in the duplications. Thus, the way that this
ASD-associated network is wired together contributes to
the understanding of the impact of these DNA deletions
and duplications.
Convergent Deletions and Duplications in Autism
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p,5%; Figure 1 and Table S3). For 3 CNV sets, namely AGP,
Marshall et al. and Levy et al., we also identified a significant excess
of genes associated with abnormal CNS synaptic transmission pheno-
types in mice, thereby triplicating this association (AGP 3.0-fold
enrichment, p=761025, BH-adjusted p,5%; Marshall et al. 2.1-
fold enrichment, p=161024, BH-adjusted p,5%; Levy et al. AGP
2.2-fold enrichment, p=561025, BH-adjusted p,5%; Sanders et
al. 1.6-fold enrichment, p=0.008, BH-adjusted p.5%; Table 1,
Table S3).
Genes previously implicated in ASD are also associated
with these model phenotypes
We next sought to determine whether model phenotypes
enriched among the mouse orthologues of genes previously
Figure 1. Relationships of mouse model phenotypic terms enriched among genes overlapped by de novo CNVs identified in
individuals with ASD. Relationships between phenotypic terms within the Mammalian Phenotype Ontology are indicated by a blue arrow running
from the child term to the parent term. Terms are significant (BH-adjusted p,5%) in at least one of 4 sets of de novo CNVs identified in individuals
with autism if they are shown with a coloured border (red, dark and light blue). Those terms whose significant enrichment is observed in three
independent sets, and thus triplicated, are marked with a boxed letter ‘‘T’’. Panels A–E show representative clusters of Behaviour/Neurological
phenotypic category, while Panel F shows the enriched phenotypes from the Nervous System phenotypic category and Panel G shows representative
enrichments from the Hearing/Vestibular/Ear phenotypic category. The number adjacent to the phenotypic terms indicates the rank of that
phenotypic term among those phenotypes significantly enriched among a set of 22 disease genes previously implicated in ASD (see Results).
doi:10.1371/journal.pgen.1003523.g001
Table 1. Triplicated mouse model phenotype associations among genes overlapped by sets of de novo CNVs identified in
individuals with ASD.
MGI mouse model
phenotype
Mammalian
Phenotype
Ontology
identifier Phenotype definition
ASD de novo CNV
sets significantly
enriched
Enrichment (rank
within category)
among AGP-Implicated
genes
Enrichment among
AGP control CNVs
Abnormal Synaptic
Transmission
MP:0003635 Defect in the communication
from a neuron to a target
across a synapse
AGP-All (2.5-fold),
Marshall-All (2-fold),
Levy-All (2.1-fold)
5.5-fold (3) 1.2-fold
Abnormal CNS synaptic
transmission
MP:0002206 Defect in the communication
from a neuron to a target
across a synapse in the
central nervous system
AGP-All (3-fold),
Marshall-All (2.1-fold),
Levy-All (2.2-fold)
6.5-fold (1) 1.3-fold
Enrichments are given as the fold change over that expected by chance (see Materials and Methods).
doi:10.1371/journal.pgen.1003523.t001
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implicated in ASD are equivalent to those we now associate with
ASD dn CNVs. Of 36 genes that had been causally-implicated in
ASD by previous studies, as defined previously [6], phenotypic
annotations were available for the unique mouse orthologues of 26
(see Materials and Methods). We removed 4 genes that were also
overlapped by an ASD dn CNV to form a wholly independent set
of 22 genes herein termed ASD-Implicated genes (Table S4).
We observed a striking concordance between the model
phenotypes associated with the ASD-Implicated genes and those
associated with the ASD dn CNV genes despite these sets’
complete independence: the two abnormal synaptic phenotypes
with triplicated associations to ASD dn CNVs ranked 1st and 3rd
among those Nervous System-category phenotypes that were most
significantly associated with ASD-Implicated genes, while 15 of the
top 18 behavioural-category phenotypic associations among ASD-
Implicated genes were among those independently associated with
the AGP dn CNVs (Figure 1, Table 1, Table S4).
The protein products of genes that contribute to these
phenotypic associations interact
Given the repeated enrichment within independent CNV sets of
genes whose mouse orthologues are associated with abnormal
synaptic transmission phenotypes, we asked whether the protein
products of the 59 synaptic phenotype CNV genes taken from
across all sets might interact within common processes or
pathways. Even after correcting for the increased likelihood that
the products of genes with behavioural or neurological associations
interact, our analysis showed that the number of these proteins’
interactions is unexpectedly high (3.75-fold over-representation,
p=0.006; Figure 2, Table 2 and Table S5; see Materials and
Methods). When we then added the set of 36 ASD-Implicated genes,
the number of direct protein interactions increased yet further
(3.2-fold over-representation, p,0.002). Cumulatively, our results
show that many of the 59 synaptic phenotype CNV genes and 36
ASD-Implicated genes function in concert and yield similar
consequences when disrupted (Figure 2, Table 2).
Mouse model phenotypic information is available only for the
orthologues of fewer than a quarter of human genes (see Materials
and Methods). It is thus expected that not all genes within CNVs
that are causally associated with synaptic abnormalities can be
identified using this resource alone. To identify additional ASD
candidate genes, we sought all those ASD dn CNV genes whose
protein products were known to directly interact with the products
of any of the 59 synaptic phenotype CNV genes or 36 ASD-
Implicated genes. This identified an additional 174 CNV genes that
form an expanded network with a 5.4-fold interaction over-
representation (p,0.002; herein termed the ASD-associated net-
work; Figure 2, Table S5). Of these 174 additional interacting
proteins, the mouse orthologues of 74 (43%) do not yet have
phenotypic information. Of the 100 additional interacting genes
with mouse model phenotypes, 44 are known to exhibit
behavioural phenotypes, and of these 35 exhibit one or more of
the significantly associated behavioural phenotypes identified
above (Figure 1 and Table S5). Examining the more general
functional annotations of genes within the ASD-associated network
using Gene Ontology (GO) identifies convergent functional
themes that are consistent with broad synaptic functioning,
organisation and maintenance (Table S6; Summarised using
REVIGO in Figures S1, S2 and S3 [22]). This functional
coherence is supported by the observation that 192 of the 210
(91%) proteins within the ASD-associated network reside in a single
inter-connected cluster, thereby also providing known interactions
that provide pathways through which effects originating from
distinct mutations can aetiologically converge (Figure 2). Despite
their known functional interconnections, the vast majority of these
ASD candidate genes are novel (Table S5).
The 203 CNV genes singled-out through the synaptic mouse
phenotype associations and the ASD-associated network provide a
causal hypothesis for 81 (45%) of the patients considered. The
median number of candidate genes per patient is 3 (mean 3.8, s.d.
3.2) suggesting a substantial role for epistasis in ASD. The network
identified here provides not only the means for mediating epistatic
interactions but is also indicative of the deleteriousness of copy
change: Among the 22 patients that have only a single copy-
changed candidate gene, that candidate gene has on average 3
times the number of interaction partners in the network as
compared to the candidate genes from patients with multiple
candidate genes (medians 3 vs. 1, respectively, Mann-Whitney U
test p=0.002). Thus, given the known deleteriousness of disrupting
highly interacting ‘‘hub’’ genes within biological networks [23], we
propose that the disruption of multiple non-hub genes within the
autism network may be required to elicit an autistic phenotype
comparable to the singular disruption of a hub gene within the
same network.
Duplicated and deleted ASD candidate genes converge
on common aetiologies
Of the 203 CNV genes identified through the synaptic mouse
phenotype associations and the ASD-associated network, 110 (54%)
are found only in duplications while 91 (45%) are only in deletions.
We next investigated how the two directions – duplications or
deletions – of copy number change might reflect common or
divergent aetiologies. To achieve this we analysed the GO biological
process annotations assigned to duplicated and, separately, to
deleted genes for significantly over-represented terms (Table S6).
While many of the over-represented annotation terms are shared
between the deleted and duplicated gene sets, we noted a striking
difference: The deleted candidate genes are significantly enriched
only in genes that are positive regulators of biological processes
(GO:0048518, 35/82 annotated genes, 2.4-fold enrichment, BH-
adjusted p=361024) while, conversely, an enrichment of genes
that are negative regulators of biological processes is only observed
amongst the duplicated candidate gene set (GO:0048519, 34/105
annotated genes, 2-fold enrichment, BH-adjusted p=0.006;
Table 3). Each of the 4 CNV set’s candidate genes contribute to
each of these enrichments with many sets nominally significant
individually (Table S7). Furthermore, reclassifying the partially
duplicated, and therefore likely-disrupted, genes as deletions
enhances these enrichments further (Table S8). These enrichments
are complementary and thus immediately suggest a convergent
model of action in which the duplication of negative regulator
genes or the deletion of positive regulator genes both act to perturb
a common target process and affect the same outcome. The
unusually frequent deletions of positive regulators and duplications
of negative regulators enable specific and biologically-meaningful
interpretations of the ASD-associated network (see Figure 3 and
Discussion).
Discussion
This study has (i) identified among 3 independent sets of ASD dn
CNVs, and therefore triplicated, an enrichment of genes whose
mouse orthologues, when disrupted, yield an abnormal synaptic
transmission phenotype; (ii) shown that these genes’ protein products
exhibit a significantly high number of interactions between
themselves and to the products of genes previously implicated in
ASD; (iii) that this interaction network extends directly to include
many more proteins of genes affected by the ASD dn CNVs of
Convergent Deletions and Duplications in Autism
PLOS Genetics | www.plosgenetics.org 4 June 2013 | Volume 9 | Issue 6 | e1003523
Figure 2. An ASD-associated interaction network. The network is formed from direct protein-protein interactions between the products of ASD
dn CNV genes that are associated with synaptic phenotypes (shown with thicker grey border), genes previously implicated in ASD (ASD-implicated
genes), and other ASD dn CNV genes whose products directly interact with these gene’s products. Physical interactions between two proteins are
shown as an edge connecting two circles representing each gene. Genes found to be duplicated in autistic patients in this study are shown in green,
deleted genes in blue, and ASD-implicated genes in red. An alternative and more detailed view of this network is shown in Figure S6.
doi:10.1371/journal.pgen.1003523.g002
Convergent Deletions and Duplications in Autism
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Table 2. Protein-Protein Interaction (PPI) network enrichments.
Gene Set Genes Direct PPIs P-value Enrichment
Abnormal Synaptic Transmission (AST) ASD dn CNV genes 59 22 0.006 3.8-fold
AST ASD dn CNV genes + ASD-Implicated genes 90 43 ,0.002 3.2-fold
AST ASD dn CNV genes + ASD-Implicated genes+other directly-interacting
ASD dn CNV genes
233 452 ,0.002 5.4-fold
Enrichments are given as the fold change over that expected by chance (see Materials and Methods).
doi:10.1371/journal.pgen.1003523.t002
Figure 3. Distinct duplications and deletions of genes whose proteins interact within the ASD-associated network perturb pathways
in the same direction. Genes duplicated within ASD dn CNVs are indicated with green upwards arrows while those deleted are denoted by blue
downwards arrows. Previously identified ASD-Implicated genes found to be disrupted in autism patients are denoted with red downwards arrows.
The nature of the interactions/regulations between proteins/molecules are shown with different edge types (see in-figure legend). The ASD-
associated network (Figure 2) identifies several deletion/duplication pathway cascades, for example the MAPK3 pathway (see Discussion for additional
examples). Here, deletions of the MAPK3 pathway components (i.e. SYNGAP1, SHANK2, KRAS, MAPK3, PAK2, and CREBBP) and duplications of their
negative regulators (i.e. FMR1, GDI1, ARHGDIA, CAMK2B, and CAMKK2) found in autistic patients identify converging effects on the MAPK pathway,
specifically reduced CREB-dependent transcription [9,62,63,64]. CREB-dependent transcription has been implicated in neuroadaptation [20]. In
addition, increased NO* production leads to the inhibition of MAPK1/3 activity [65], which fits well with the observed CNV duplications of both NOS1
and DLG4, the latter gene promoting recruitment of NOS1 [66]. Similarly, duplication of PRKG1, which is up-regulated by NO* and expresses a product
that inhibits IP3 production, is predicted to reduced activation of the calcium-releasing IP3-receptor ITPR1 [67], which is in turn found to be deleted.
doi:10.1371/journal.pgen.1003523.g003
Convergent Deletions and Duplications in Autism
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almost half of the cohort; (iv) that the gene products in this ASD-
associated network possess roles in synaptic function, organisation
and maintenance; (v) that many individuals with ASD possess
multiple copy changed genes from the ASD-associated network; (vi)
that genes that are highly connected within the network (‘‘hub
genes’’) are significantly enriched among patients that possess only
a single ASD-associated network gene; and, finally (vii) that this
network’s genes that are deleted are significantly enriched in genes
that act to positively regulate biological processes while those that
are duplicated are significantly enriched in negative regulators.
An association of ASD CNVs with genes that yield synaptic
phenotypes when disrupted in mice has been reported before in
rare CNVs but replication was not achieved [13]. Here, despite
little overlap between the 3 CNV sets involved (Table S2E), we are
able to triplicate this association. These synaptic associations
provide aetiological insight that accords well with the emerging
neurophysiological view of a strong role for synaptic dysfunction in
autism [24]. It is also further strengthened by the over-represented
functions among genes within the broader ASD-associated network,
whose functions include vesicle transport, cell junction organisa-
tion and calcium transport (Figures S1, S2 and S3, Table S6).
However, the breadth of dysfunction suggested by the roles of
these physically-interacting proteins implicate other, more intra-
cellular processes, such as the cytoskeletal and cellular transport
processes, that may affect synapse formation, structure and/or
maintenance (Figure S1, Table S6).
The known physical interactions between these genes’ products
provide pathways through which separate genetic perturbations
can converge functionally (Figure 2, Table S5) while the
importance of a gene within the ASD-associated network, as
specified by the degree of connectivity, appears to be an indicator
of ASD-relevant deleteriousness (see Results). Recently, two large-
scale studies examining the exomes of autistic patients also
identified an excess of protein-protein interactions between genes
harbouring suspected causative mutations, reporting smaller
networks with 49 [15] and 45 [14] participating genes of which
3 genes and 2 genes, respectively, are also identified through our
network. After excluding overlapping genes and compared to
random gene sets of equivalent size, the number of connections
between gene products in each of the O’Roak et al. and Neale et al.
reported networks to the network we identify here are 12-fold and
38-fold over-represented, respectively (p,0.002 for both). Thus,
despite little overlap in genes, the strong interconnectedness
between these networks identifies pathways through which cellular
perturbations arising from distinct mutations identified in separate
studies may converge. The single nucleotide variants (SNVs)
detected in these two published exome studies are largely
predicted to be harmful to the function of the encoded proteins,
and therefore comparable to the copy number deletion events in
our study. Corroborating our finding of an enrichment of genes
that positively regulate among deletions, we also observe a highly
significant enrichment of positive regulators among the more
strongly-interconnected set of genes identified by Neale et al. (2.7-
fold enrichment, p=3.861026, BH-adjusted p,0.05) which, while
enriched, is not significant among the less well-connected genes
reported by O’Roak et al. (1.4-fold enrichment, p.0.05).
Despite chronologically limiting our mouse phenotypic dataset
to avoid bias (see Materials and Methods), the similarities between
the behavioural mouse phenotypes associated with the AGP dn
CNVs and human ASD presentations appear clear, with abnormal
social/conspecific interaction, stereotypic behaviour and abnormal memory/
learning/conditioning phenotypes all over-represented (Figure 1).
Many of our study’s ASD-associated phenotypes bear a striking
resemblance to other frequently co-occurring symptoms, such as
impaired coordination [25,26,27], anxiety-related phenotypes [28],
and absence and tonic-clonic seizures [29,30,31] (Figure 1). Finally, we
observe a strong enrichment of genes whose disruption yields
hearing phenotypes in mice. This observation accords well with
estimates in the literature that hearing abnormalities (including
sensorineural hearing disorders) affect between 33–46% of ASD
cases (Figure 1G) [32,33]. Many of the associated hearing, and
some nervous system, mouse phenotypes are related to peripheral
hearing abnormalities, particularly concerning the cochlea and
mechanoreception (Figure S4 and Table S3). Inner ear mecha-
noreception abnormalities appear to have received little attention
compared to other regions involved in auditory reception and
processing [33]. This is despite improvements in hearing following
cochlear implants in individuals with ASD [34] and the knowledge
that rare mutations in several genes implicated in ASD (including
CHD7, NIPBL, PTPN11 and TBX1) can cause inner ear
abnormalities in humans [35,36,37,38].
The enrichment of deleted genes in the network that positively
regulate biological processes and a complementary enrichment of
duplicated genes that negatively regulate biological processes
suggest the occurrence of convergent aetiologies whereby both
deletions and duplication act to perturb biological processes
relevant to autism in the same direction (Figures 2 and 3). Indeed,
the interactions within the ASD-associated network reveal this
proposition to be consistent with the experimental literature. For
example, considering the STX1A/CFTR/SLC6A3 (aka. DAT)
interactions (Figure 3), over-expression of STX1A decreases DAT
dopamine transport activity [39], and reduces the CFTR-
mediated chloride current by inhibiting trafficking of CFTR to
the cell surface [40]. These findings predict that over-expression of
STX1A yields an effect similar to the deletion of DAT or CFTR
and, concordantly, whereas STX1A lies within a duplication,
CFTR and DAT are each deleted. Furthermore, STX1A also
interacts with SYP (also duplicated), which negatively regulates
Table 3. Regulatory GO enrichments amongst ASD dn CNVs candidate genes.
Copy Change Direction
Total GO
genes Positive regulators (GO:0048518) Negative Regulators (GO:0048519)
Genes
BH-adjusted
p-value Enrichment Genes
BH-adjusted p-
value Enrichment
Duplications 105 24 (23%) .1 1.3-fold 34 (32%) 0.006 2.0-fold
Deletions 82 35 (43%) 0.0003 2.4-fold 24 (29%) 0.08 1.8-fold
The set of candidate genes was defined as those CNV genes associated with Abnormal Synaptic Transmission mouse phenotypes (Table 1) and those CNV genes
identified through direct protein-protein interactions (Table 2). Enrichments are given as the fold change over that expected by chance (see Materials and Methods).
doi:10.1371/journal.pgen.1003523.t003
Convergent Deletions and Duplications in Autism
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SNAP proteins (SNAP29 is deleted) [41,42]. SNAP proteins are key
to presynaptic exocytosis, a process also likely to be disturbed by
altered calcium homeostasis resulting from the array of deleted
voltage-dependent calcium channels (CACNA1B [deletion],
CACNA1C [ASD-implicated deletion], and CACNA1H [deletion])
[43] (Figure 3).
Another example of apparent convergence in aetiology and
outcome are the copy number changes affecting the PI3K/Wnt
pathways (Figure 3). Here, many copy number changes are
predicted to converge to reduce or disrupt the action of the b-
catenin destruction complex in the Wnt/b-catenin signalling path-
way; the deletion of AXIN1, the increased ubiquitination of
AXIN1 by duplication of UBC [44] or the disruption of the PI3K
pathway due to mutations in PTEN, TSC1, or TSC2 [45] (Figure 3).
Perturbations affecting AXIN1in ASD include the duplication of
DVL2 which inhibits AXIN1 (deleted) function [46]. Furthermore,
as NKD family proteins promote the degradation of DVL proteins
[47,48], the deletion of NKD2 may increase the activities of DVL2
and thereby also inhibit AXIN1. Concordant with a decrease in b-
catenin degradation, an increase in b-catenin stabilization could
result from LRPAP1, NKD2 and DVL2 copy number changes.
LRPAP1 is thought to have protective roles in LRP1 trafficking
and its duplication may therefore increase LRP1 availability [49].
The outcome of the copy number change and disruption of each
of these genes is likely to up-regulate the Wnt-stimulated TCF/
LEF-dependent transcription, a pathway whose down-regulation
has been proposed to have therapeutic benefits in ASD models
[50,51,52].
Given the ever-increasing number of genetic variants that thus
far have been implicated in ASD, the focus will inevitably shift
from enumeration towards understanding how these variants
contribute to the common pathways and processes underlying this
complex disease. Here we have identified a large network of
interacting proteins affected by copy number variants identified in
patients with ASD, and shown how the network topology and
direction of copy number change can be used to interpret these
variants’ pathway perturbations. Therapeutically targeting mole-
cules at the ends of pathologically-perturbed regulatory cascades
may provide more broadly-applicable treatments, while patholog-
ical gene duplications may identify attractive targets for knock-
down therapeutics as a means of ameliorating perturbed pathways.
Materials and Methods
De novo CNVs identified in individuals with ASD
Four sets of de novo CNVs were employed in this study (Table
S1), of which two are drawn from the Simons Simplex Collection
and thus overlap [53]. The largest set consists of 73 de novo CNVs
identified in 54 (out of 996) individuals with strict autism by the
Autism Genome Project (AGP; Table S1) [6]. Of these, 39 CNVs
had been confirmed as de novo by independent methods while 34
were considered likely to be de novo by the CNV calling algorithms.
The second set consisted of 28 de novo CNVs identified in 24
patients reported in a study by Marshall et al. [54]; two patients
who had been reanalysed by the AGP have been removed; Table
S2. The third set consisted of 94 de novo CNVs identified in 82
patients reported in a study by Levy et al. [20] and the fourth set
consisted of 67 de novo CNVs identified in 63 patients reported in a
study by Sanders et al. [55]. Forty two patients examined by Levy et
al. were also present in the study by Sanders et al. but this does not
affect our findings; As the synaptic phenotype associations that we
report and take forward in the Results were identified amongst
both the AGP and the Marshall et al. sets, neither the Levy et al.
nor Sanders et al. sets were required for replication and thus these
latter sets non-independence from each other does not undermine
this association. For all sets, contributing patients have been
evaluated as having ASD according to ADI-R and/or ADOS
criteria. Herein, de novo CNVs identified in patients with ASD is
termed ‘‘ASD dn CNVs’’.
Assigning genes to CNVs
Human genes were assigned to ASD dn CNVs according to
Ensembl Ensmart54 [56]. To be confident that the expressed
coding sequence of a gene is affected by the copy number change,
we conservatively required at least one coding exon of every
known transcript of a gene to be overlapped by a CNV for that
gene to be deemed overlapped (Table S2). Particular consideration
was given to showing that our gene assignment procedure and
statistical over-representation analyses did not yield any functional
bias under the null hypothesis (see Figure S5 and Methods S1).
Genes observed to be copy number variable in the same direction
(gain/loss) within a set of CNVs employed by the AGP as a
control, i.e. identified from individuals with no obvious psychiatric
history in a previous study were removed from the ASD dn CNV
gene lists because these are less likely to be associated with ASD
[6]. Although it remains possible that common variants contribute
to ASDs, our study focuses on genes affected by rare, de novo
variants (see Introduction).
Mouse Genome Informatics (MGI) phenotypes
Annotations of phenotypes resulting from disruptions of mouse
orthologues of these affected genes were obtained from the Mouse
Genome Informatics (MGI) resource (http://www.informatics.jax.
org) and interpolated as described previously [12,57,58,59]. Using
simple, unambiguous, 1:1 gene orthology relationships from the
MGI resource, 5,283 distinct MGI phenotypic terms were mapped
to 5,671 human genes. Each phenotype belongs to one or more of
33 over-arching categories. We considered only 4,055 reasonably
populated phenotypes, defined as those with at least 1% of all genes
associated with the relevant phenotypic category, thereby reducing
uninformative results and improving methodological power. As an
unreplicated association between genetic variants in autism patients
and a mouse model phenotype was reported in April 2010 [13], we
employed only those phenotypes reported in the MGI resource
prior to this date, thereby reducing any subsequent phenotyping
bias or consequential circularity in discovery. However, our findings
remain, or are strengthened by, those more recently reported mouse
model phenotypes (data not shown).
Protein-protein interactions
We employed DAPPLE: Disease Association Protein-Protein
Link Evaluator [60] to identify direct protein-protein interactions
among the protein products of the genes contributing to functional
enrichments. A protein-protein interaction network’s connectivity
was calculated as published previously [60]. Enrichment analysis
was carried out by comparing the number of identified direct
protein interactions with the average of those identified from 500
gene sets, in which genes were randomly sampled while matched
in set size. To account for the increased likelihood that genes that
share behavioural associations are more likely to interact than
randomly selected genes, we randomly selected sets of orthologues
from 1,766 genes annotated with behaviour and neurological
phenotypes in the MGI.
Statistical analysis
Due to the small numbers of de novo CNVs considered here and
a lack of a control set of de novo CNVs, performing a case-control
Convergent Deletions and Duplications in Autism
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comparison is not possible. Thus, employing the one-sided Fisher’s
exact test, we tested the null hypothesis that a (mouse) phenotype
associated with (human) Ensembl genes overlapping a set of ASD-
associated CNV genomic intervals occurs at a frequency that is no
different from that expected from the genome as a whole.
Randomisations confirmed that this approach did not yield
artefactual bias (see Methods S1 and Figure S5). A multiple
testing correction, BH-adjusted p,5%, was applied to account for
number of functional terms (phenotypes or GO terms) tested when
examining a given gene set [61].
Supporting Information
Figure S1 REVIGO-summarised Biological Process Gene
Ontology terms enriched within the combined set of ASD dn
CNV genes that are associated either with an abnormal synaptic
transmission phenotype in the mouse or whose protein product
directly interacts with an ASD dn CNV gene that is associated with
this phenotype (Supek et al., 2011; The Gene Ontology
Consortium et al., 2000). The summarised GO terms are given
in full and separately for deletions and duplications in Table S6.
(TIFF)
Figure S2 REVIGO-summarised Cellular Location Gene
Ontology terms enriched within the combined set of ASD dn
CNV genes that are associated either with an abnormal synaptic
transmission phenotype in the mouse or whose protein product
directly interacts with an ASD dn CNV gene that is associated with
this phenotype (Supek et al., 2011; The Gene Ontology
Consortium et al., 2000). The summarised GO terms are given
in full and separately for deletions and duplications in Table S6.
(TIFF)
Figure S3 REVIGO-summarised Molecular Function Gene
Ontology terms enriched within the combined set of ASD dn
CNV genes that are associated either with an abnormal synaptic
transmission phenotype in the mouse or whose protein product
directly interacts with an ASD dn CNV gene that is associated with
this phenotype (Supek et al., 2011; The Gene Ontology
Consortium et al., 2000). The summarised GO terms are given
in full and separately for deletions and duplications in Table S6.
(TIFF)
Figure S4 Enriched cochlear and mechanoreception-associated
mouse model phenotypes among orthologues of genes overlapped
by Gain de novo CNVs from the AGP set. Panel A shows the
relevant terms that were identified among Nervous System category
phenotypes while Panel B shows the relevant terms that were
identified among Hearing/Vestibular/Ear category phenotypes.
Relationships between phenotypic terms within the Mammalian
Phenotype Ontology are indicated by a blue arrow running from
the child term to the parent term. Terms are significantly enriched
(BH-adjusted p,5%) if they are shown with a blue border.
(TIFF)
Figure S5 Distributions of p-values for the surfeits of genes
associated with 3 phenotypic categories obtained for 500
randomised sets of case-matched CNVRs. 500 sets of genomic
regions matched in size and number to each of the Loss and the
Gain CNVRs were obtained (see Materials and Methods). For each
set, the likelihoods for the observed surfeit of genes associated with
a particular phenotypic category, namely Behavior[/Neurological],
Nervous System and Hearing/Vestibular/Ear, were recorded and a
histogram charted. See also Methods S1.
(TIFF)
Figure S6 An alternative view of the ASD-associated interaction
network shown also in Figure 2. The network is formed from
direct protein-protein interactions between the products of ASD dn
CNV genes that are associated with synaptic phenotypes (shown in
with thicker grey border), genes previously implicated in ASD
(ASD-implicated genes), and other ASD dn CNV genes whose
products directly interact with these gene’s products. Physical
interactions between two proteins are shown as an edge
connecting two circles representing each gene. Genes found to
be duplicated in autistic patients in this study are shown in green,
deleted genes in blue, and ASD-implicated genes in red.
(TIFF)
Methods S1 Statistical analysis and gene assignment. Support-
ing materials for our method of gene assignment and confirming
the null of statistical analysis. See also Figure S5.
(DOC)
Table S1 Genomic extent and ENSEMBL gene content for
ASD-associated de novo CNVs and AGP control CNVs. In CNV
datasets, the genes considered are those remaining after excluding
genes also overlapped by benign CNVs in the same direction of
copy change (see Materials and Methods). Sets termed All are
formed by combining both Gain and Loss CNVs.
(XLSX)
Table S2 (5 sheets): De novo CNVs identified in individuals with
ASD employed in this study: Sheet A lists the de novo CNVs
reported by the Autism Genome Project (AGP), Sheet B lists the de
novo CNVs reported in the Marshall et al. study, Sheet C lists the de
novo CNVs reported in the Levy et al study and Sheet D lists the de
novo CNVs reported in the Sanders et al study. Sheets A–D provide
the genomic location (NCBI36) and copy change for the AGP set
of CNVs employed in this study. Sheet E details the overlapping
sequence between the three sets of de novo CNVs considered in the
study. The total amount of sequence covered by each set is given
next to the set name in the row headings. The percentage shown
in brackets in the main body gives the proportion of the set listed
in the row heading that is overlapped by the set listed in the
column headings.
(XLS)
Table S3 (11 sheets): Significantly enriched mouse model
phenotypes among the orthologues of genes overlapped by 3
independent sets of de novo CNVs identified in individuals with
ASD: Sheets (A–E) AGP de novo CNVenrichments, sheets (F–H)
Marshall et al. de novo CNV enrichments, and sheets (I–K) Levy et
al. de novo CNV enrichments. For AGP enrichments (sheets A–E),
the attached excel spreadsheet provides 5 spreadsheets/tables: one
sheet/table each for enrichments in three phenotypic categories
Behaviour/Neurological (sheet A), Hearing/Vestibular/Ear (sheet B) and
Nervous System (sheet C); The AGP candidate genes identified
through these enrichments (sheet D); and the AGP CNVs for
which candidate genes have been identified (sheet E). For the
Marshall et al. enrichments, 3 spreadsheets/tables are provided:
the enrichments in the phenotypic category Nervous system (sheet F);
The Marshall et al. candidate genes identified through these
enrichments (sheet G); and the Marshall et al. CNVs for which
candidate genes have been identified (sheet H). For the Levy et al.
enrichments, 3 spreadsheets/tables are provided: the enrichments
in the phenotypic category Nervous system (sheet I); The Levy et al.
candidate genes identified through these enrichments (sheet J); and
the Levy et al. CNVs for which candidate genes have been
identified (sheet K). Phenotype tables: PhenotypeID is the
Mammalian Phenotype Ontology identifier. PhenotypeName
(Abbreviation: Total Genes in Genome with Phenotype) provides
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the phenotype name. Within the brackets, the phenotype
abbreviation for use in other tables is given first, while the second
number gives the total number of human orthologues with a
mouse orthologue that yields this phenotype when disrupted.
CopyChangeSet =ALL|GAIN|LOSS gives the direction of copy
change of the CNVs whose overlapping genes possess this
enrichment. Percentage Increase is the enrichment of genes
associated with this phenotype over that expected from the genome
by chance (see Materials and Methods). P-value is the associated
probability for this enrichment (hypergeometric probability, BH-
adjusted p,5%). Number of Genes forming Enrichment is the
number of overlapped genes that contribute to this enrichment.
Total Genes in CNV Set gives the number of genes with this CNV
set for which phenotypic information is available. Number of ASD
implicated genes hit by enrichment gives the number of genes
within this enrichment that also belong to a set of 26 genes that have
both been previously implicated in ASD as defined by the AGP
Consortium and for which phenotypic information is available.
Number of CNV hits (unique CNVs, percentage of CNVs) gives the
total number of genes from this enrichment that overlap a CNV
within this set. In parenthesis, the first number is the number of
unique CNVs from this set that are overlapped by at least one gene
from this enrichment, while the second number gives the proportion
of all CNVs within this set that are overlapped. Number of patients
hits (unique patients, percentage of patients) gives the total number
of genes from this enrichment that overlap a de novo CNV within a
patient from this cohort. In brackets, the first number is the number
of unique patients from this set that possess a de novo CNV that is
overlapped by at least one gene from this enrichment, while the
second number gives the proportion of all patients within this cohort
that possess a CNV that is overlapped. Genes hit lists the genes that
contribute to this enrichment. Ensgs hit gives the ENSEMBL ids for
the contributing genes. CNVs hit gives the CNVs that are
overlapped by genes from this enrichment. The CNV format is
[cnv_identifier]_chr[chromosome]_[gain/loss]_[chromosome start
position]. Candidate Gene Table: GENE is the gene name, ENSG
is the ENSEMBL identifier, Phenotypic enrichments contributed to
lists the enriched phenotypes for this set to which this gene
contributes. The phenotypic abbreviations are listed in the
phenotypic enrichment table(s) for this CNV set in the previous
spreadsheet/table within this excel workbook. Number of CNVs
gives the number of CNVs in this set that candidate gene overlaps.
CNVs lists the particular CNVs overlapping this gene (see
phenotype sheet/table for format description). Patients lists the
patients possessing these CNVs. CNVs hit Table: CNV gives the
CNV from this set that is overlapped by a candidate gene (see
phenotype sheet/table for format description). Number of Candi-
date Genes hit is the number of genes that contribute to the
significant enrichments observed for this set of CNVs that are
overlapped by this particular CNV. Genes (enriched phenotypes)
lists the overlapped candidate genes and gives abbreviations for the
enriched phenotypes that this gene contributes to - see phenotype
tables/sheets for abbreviation listings.
(XLS)
Table S4 (5 sheets): Significantly enriched mouse model
phenotypes among the orthologues of 22 genes that have been
implicated in ASD as defined by the AGP Consortium. (A) ASD
Implicated Genes lists twenty two human genes deemed previously
to have been implicated in ASD (termed ASD-Implicated genes).
These genes are a subset of 36 disease genes deemed causally
implicated in ASD by the Autism Genome Project (Pinto et al.,
2010), and was formed by retaining only those genes whose mouse
orthologue’s disruption had been phenotyped and discarding those
genes that were overlapped by ASD dn CNVs considered in this
study. (B) Categories lists the enriched Mammalian Phenotype
Ontology categories: (C) Nervous System, (D) Behavior/Neuro-
logical, (E) Lethality-Postnatal each list the finer phenotypes
enriched within each of these categories respectively. The
probability is that obtained through the hypergeometric test
(BH-adjusted p,5%). Total Genes with Phenotype gives the total
number of human genes whose mouse orthologue is associated
with this phenotype. Set Genes with Phenotype is the total number
of genes within the set whose mouse orthologue is associated with
this phenotype. Percentage change over expected is that obtained
when compared with the genome as whole sampled randomly.
(XLS)
Table S5 (6 sheets): Candidate ASD CNV genes identified in
this study. (A) All CNV candidate genes are listed, along with the
ASD dn CNVs that harbour them. PPI partner(s) lists other
candidate genes whose proteins directly interact with the protein
product of the listed gene. (B) 59 ASD dn CNV genes whose mouse
orthologues’ disruption yield a synaptic phenotype. (C) 144 ASD
dn CNV genes whose protein products interact with the protein
products of either the ASD dn CNV genes whose mouse
orthologues’ disruption yield a synaptic phenotype listed in sheet
B or the 22 ASD-Implicated genes listed in Table S4. (D) Each ASD
dn CNV with a candidate gene is listed along with the candidate
genes proposed by this study. Total Genes Considered lists the
number of protein-coding genes within that CNV. (E) Each
patient with autism for whom a candidate gene is proposed in this
study is listed. (F) 1:1 PPI partners and DAPPLE network
parameters.
(XLS)
Table S6 Gene Ontology terms significantly enriched among
204 candidate genes identified in this study. Probability is the
associated P-value for this enrichment (hypergeometric test, BH-
adjusted p,5%). Total Genes in Genome with annotation gives
the total number of human genes annotated with this GO term.
Sample Genes with annotation is the total number genes within
the set annotated with this GO term. % difference over expected is
that obtained when compared with the genome when sampled
randomly.
(XLS)
Table S7 Genes annotated with GO terms ‘‘positive regulation
of biological process’’ (GO:0048518) and/or ‘‘negative regulation
of biological process’’ (GO:0048519) within each set of de novo
CNVs considered in this study. The p-value is the raw uncorrected
value derived from comparison to all genes. ‘‘%Change’’ gives the
percent change over or under that expected against the
background of all genes.
(XLSX)
Table S8 Regulatory GO enrichments amongst ASD dn CNVs
candidate genes after reclassifying partially-duplicated genes as
deleted. The candidate genes considered here are the subset of
CNV genes whose orthologues have synaptic phenotypes in mice
plus other CNV genes whose protein products directly interact
with the synaptic genes’ proteins. If the outcomes of many of these
genes’ duplications result in the increased down-regulation of their
targets, then each such gene would be expected to be duplicated
largely in its entirety for the duplication to be functional. Indeed,
after removing partially-duplicated genes, we find that the
enrichment of duplicated genes that negatively regulate biological
processes increases (32/92 genes, +119% enrichment, BH-
adjusted p=0.005; Table 1). Concomitantly, including the
partially-duplicated genes that would be expected to functionally
resemble deletions, with the deleted genes maintains the
Convergent Deletions and Duplications in Autism
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enrichment of positive regulators (40/95 genes, +134% enrich-
ment, BH-adjusted p=261025; Table 1). Corroboratively, the
proportions of genes that regulate in the opposite direction to the
proposed general model (i.e. the opposite being positively
regulating candidate genes in deletions and negatively regulating
candidate genes in duplications) are reduced when considering
partially duplicated genes as deleted genes.
(XLSX)
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